I the ROLE of BOTANICAL OILS ENRICHED in FADS2-DERIVED N
Total Page:16
File Type:pdf, Size:1020Kb
THE ROLE OF BOTANICAL OILS ENRICHED IN FADS2-DERIVED N-3 VS. N-6 POLYUNSATURATED FATTY ACIDS IN PREVENTION OF ATHEROSCLEROSIS BY SWAPNIL VIJAY SHEWALE A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Physiology and Pharmacology AUGUST 2015 Winston Salem, North Carolina Approved By: John S. Parks, Ph.D., Advisor Martha Alexander-Miller, Ph.D., Chairman Michael C. Seeds, Ph.D. Kylie Kavanagh, Ph.D. Ann Tallant, Ph.D i DEDICATION This dissertation is dedicated to my very loving and sweet grandmothers: Manjulabai Kashinath Shewale (paternal) from Takali, India and Janakibai Ramchandra Hire (maternal) from Malegaon, India. My maternal and paternal grandparents were particularly keen on providing education to their children despite all odds. My largely joint family of 20 some uncles and aunts, parents: Vidhya and Vijay Shewale and in-laws: Jayashri and Sharad Sonawane have encouraged all of us, including me and my loving and beautiful wife- Poonam, my brother- Himanshu, my sister- Swati and ~30-50 some cousins to embrace similar ideologies and to pursue our interests. My grandmothers to me are the silent sufferers and reformers of our lives. ii ACKNOWLEDGEMENTS First and foremost, I would like to thank Dr. John S. Parks for his guidance, support, patience and encouragement throughout the last five years of training. I can recall many-many occasions when I may have made mistakes, asked redundant questions or spoken “too-much, too-soon”. However, Dr. Parks has always been patient with me “to get it together” and to progress as an advanced PhD candidate. It’s his originally well thought-out Botanical grant, collaborations with other established PI’s, and allowing me to navigate my way through has made this dissertation possible. I would also like to thank Dr. Rudel for his rare but extremely insightful comments, advice and for putting the original Jornal Club, Seminar and Guest-speaker series together. In the Lipid Sciences Department, there always was something to learn from every presenter every week. I am extremely fortunate and grateful to (family) members of the Parks lab and the Lipid Sciences Department. Everyone on the “Lipid” floor welcomed, helped and taught me everything I could learn during my PhD here. I can’t forget to thank other members from the Lipid group: Elena, Kaiser, Martha, Matt, Xuewei, Amanda-Mark, and Xin. Elena made everything so easy like every mom does and also saved my life once. Amanda-Mark allowed me to stay in their vacant house when I was temporarily homeless. I would also like to specially thank Dr. Miller, for her guidance with design, execution and interpretation of flow-cytometry related experiments, Dr. Seeds for insights, and encouragement and Dr.’s Tallant and Kavanagh for their support, critique and evaluation of my progress as a researcher. I would also like to thank my previous mentor Dr. Mariana Morris for “pushing” me to accept the offer from Wake. The Department of Physiology and Pharmacology not only accepted me but encouraged me to foster, explore and contribute in scientific, teaching, business development and social areas as their brand ambassador. I am eternally grateful for this experience and journey which has allowed me to look forward to my future with optimism. iii TABLE OF CONTENTS LIST OF FIGURES AND TABLES………………………………...……….…….…............. V LIST OF ABBREVATIONS…………………………………………………..…….………..... VIII ABSTRACT........................................................................................................................ XI CHAPTER: I. INTRODUCTION..................................................................................................1 II. BOTANICAL OILS ENRICHED IN N-6 AND N-3 FATTY ACID PRODUCTS OF FADS2 ARE EQUALLY EFFECTIVE IN PREVENTING ATHEROSCLROSIS AND HEPATOSTEATOSIS IN MICE .............................................................................52 III. IN VIVO ACTIVATION OF LEUKOCYTE GPR120 BY POLYUNSATURATED FATTY ACIDS HAS MINIMAL IMPACT ON ATHEROSCLROSIS IN LDLrKO MICE......102 IV. DISCUSSION...................................................................................................166 CURRICULUM VITAE.......................................................................................................185 iv LIST OF FIGURES AND TABLES CHAPTER I: Figure 1. Outline of lipoprotein transport and metabolism ……………………………………....9 Figure 2. Outline of biosynthesis and metabolic pathways for polyunsaturated fatty acids …24 Table 1. Classification of circulating lipoproteins………………………………………………….5 Table 2. Major enzymes important to lipoprotein metabolism ………………………………….10 Table 3. Mouse models of atheroscleroses ………………………………………………………20 CHAPTER II: Figure 1. Body weight gain and terminal liver/body weight ratios……………………………….91 Figure 2. RBC fatty acid (FA) composition. ……………………………………………………....92 Figure 3. Percentage fatty acid composition of plasma and liver lipids………………………....93 Figure 4. Plasma lipid concentrations……………………………………………………………...94 Figure 5. Plasma lipoprotein cholesterol distribution……………………………………………...95 Figure 6. Hepatic VLDL-TG secretion rate. ……………………………………………………….96 Figure 7. Hepatic response to atherogenic diets. ………………………………………………...97 Figure 8. Aortic atherosclerosis. …………………………………………………………………...98 Figure 9. Mouse atherosclerotic plaque oxidized cholesteryl ester analysis. ……………….....99 Figure 10. LPS-stimulated eicosanoid release from peritoneal macrophages. ……………….100 Figure 11. Macrophage inflammation, foam cell formation, and chemotaxis. ………………...101 Table 1. Atherogenic Diet (AD) percentage fatty acid composition (%FA) and percentage total energy equivalence (% EE) of individual fatty acid…………………………………………….….89 v CHAPTER III: Figure 1. L-GPR120 does not affect plasma lipids…………………………………………...131 Figure 2. L-GPR120 does not affect plasma lipoprotein cholesterol distribution…………..132 Figure 3. Effect of L-GPR120 on hepatic M1-M2 and lipogenic genes, neutral lipid content and inflammatory cytokines. …………………………………………………………………....133 Figure 4. Effect of L-GPR120 on neutrophilia and monocytosis. …………………………...134 Figure 5. Effect of L-GPR120 on monocyte recruitment to aortic root intima………………135 Figure 6. Histological quantification of aortic root atherosclerotic lesions…………………..136 Figure 7. Effect of L-GPR120 on aortic cholesterol content. ………………………………..137 Supplementary Table 1: Atherogenic Diet (AD) percentage fatty acid composition (%FA) and percentage total energy equivalence (% EE) of individual fatty acid……………………….145 Supplementary Figure 1. Bone marrow transplantation (BMT) efficiency. ………………...152 Supplementary Figure 2. Body weight gain and terminal body weights…………………….153 Supplementary Figure 3. Terminal organ/body weight ratios ……………………………….154 Supplementary Figure 4. RBC fatty acid (FA) composition…………………………………..155 Supplementary Figure 5. Liver Histology……………………………………………………….156 Supplementary Figure 6. Effect of L-GPR120 on circulating monocytosis. ………………...157 Supplementary Figure 7. Monocyte recruitment experiment. ………………………………. 158 Supplementary Figure 8. Representative aortic root atherosclerotic lesions stained for Oil-red-O. …………………………………………………………………………….159 Supplementary Figure 9. Representative aortic root atherosclerotic lesions stained for CD68/ macrophages. ……………………………………………………………….160 vi Supplementary Figure 10. Representative aortic root atherosclerotic lesions stained for Sirius red/ collagen…………………………………………………………..………161 Supplementary Figure 11. Representative aortic root atherosclerotic lesions stained for CD11c/ dendritic cells……………………………………………………………….162 Supplementary Figure 12. Representative aortic root atherosclerotic lesions stained for cleaved-caspase-3/ apoptotic cells………………………………………………..163 CHAPTER IV: Figure 1. Summary of potential pathways for decreased inflammation by n-6 and n-3 fatty acids ……………………………………………..…………….…………..175 vii LIST OF ABBREVIATIONS 13-HODE 13-hydroxyoctadecadienoic acid 15-HETE 15-hydroxyeicosatetraenoic acid 15d-PGJ2 15-Deoxy-delta 12,14-prostaglandin J2 ABCA1 ATP-binding cassette transporter A1 AP-1 activator protein 1 apoE apolipoprotein E apoEKO apolipoprotein E knockout Arg-1 arginase-1 CCR2 C-C chemokine receptor type 2 CCR7 C-C chemokine receptor type 7 CD cluster of differentiation CHD coronary heart disease COX cyclooxygenase CVD cardiovascular disease CX3CR1: CX3C chemokine receptor 1 DART The Diet and Reinfarction Trial DGLA dihomo-gamma-linolenic acid DHA docosahexaenoic acid EPA eicosapentaenoic acid GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico GLA gamma-linolenic acid Gr-1 granulocyte differentiation antigen 1 HDL high density lipoprotein viii IFN-γ interferon gamma IL-1 interleukin 1 iNOS inducible nitric oxide synthase JELIS Japan EPA Lipid Intervention Study LP lipoprotein LDL low density lipoprotein LDLr low density lipoprotein receptor LDLrKO low density lipoprotein receptor knockout LO lipoxygenase LP lipoprotein LPS lipopolysaccharide LXR liver X receptor Ly6C lymphocyte antigen 6 C Ly6G lymphocyte antigen 6 G mmLDL minimally modified LDL MMP matrix metalloproteinase MR mannose receptor NCoR nuclear receptor corepressor NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells oxLDL oxidized LDL PIAS1 protein inhibitor of activated STAT1 PPAR peroxisome-proliferator activated receptor SDA stearidonic acid SMC smooth muscle cell STAT signal transducers and activators